Miloxacin, a synthetic antibacterial agent structurally related to oxolinic acid, has a broad spectrum of activity in vitro against gram-negative bacteria and considerable activity in vivo against infections with these bacteria. These observations led to studies on the absorption and excretion of miloxacin in mice, rats, and dogs after administration of a single oral dose. Studies on oxolinic acid have been included for comparison. Peak serum levels of miloxacin, attained 1 h after administration of 20, 50, and 100 mg/kg to rats and dogs, were approximately 20, 40, and 60 ,Ag/ml, respectively. Peak levels in mice receiving the same dose were 15, 60, and 80 ,ug/ml at 0.5 h. Peak serum levels of oxolinic acid were attained 0.5 to 1 h later than the above times at comparable doses and were one-half to onefourth those of miloxacin. Urinary recovery of miloxacin at the above doses ranged from 3.2 to 6.5% during the 24-h posttreatment period. Recoveries of oxolinic acid were one-half to one-fifth those of miloxacin. At a 50-mg/kg dose, rats excreted 4.6% of the miloxacin in bile in the 20-h posttreatment period.
Miloxacin (1), 5,8-dihydro-5-methoxy-8-oxo-2H-1, 3-dioxolo-[4,5-g] -quinoline -7 -carboxylic acid, closely related to oxolinic acid (5) in structure, has exhibited a broad spectrum of antibacterial activity in vitro and is especially active against gram-negative bacteria (3) . Miloxacin also has significant activity in single-or two-dose regimens against infections with Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, or Serratia marcescens in mice (3) . These findings led to studies of the absorption and urinary excretion of this compound after administration of single oral doses to mice, rats, and beagle dogs and the biliary elimination of this compound in rats. Studies on the absorption and urinary excretion of oxolinic acid have been included for comparison.
MATERIALS AND METHODS
Test compounds. The preparations of miloxacin and oxolinic acid used in the current experiments were synthesized in our laboratory (1, 5) . The structures and purities were confirmed by comparison to authentic compounds by infrared, nuclear magnetic resonance, and mass spectra and thin-layer chromatography.
Drug administration. Micronized samples of miloxacin and oxolinic acid were suspended in 0.5% aqueous carboxymethylcellulose solution and administered within 1 h of preparation. Mice, rats, and beagle dogs were fasted for 12 to 14 h before administration of single doses of 20, 50, and 100 mg/kg by gavage. The dosed animals were held in metabolism cages suitable for each species; food was withheld for 4 h after administration.
Studies in mice. A total of 360 male ICR mice weighing approximately 20 g were used. Fifteen groups, of 10 mice each, were dosed with miloxacin (5 groups for each dose). Animals were decapitated 0.5, 1, 2, 4, and 8 h after dosage. Blood from each group was pooled, kept at room temperature for 0.5 h, and centrifuged at 2,500 rpm to obtain serum, which was immediately frozen and stored at -20°C until assayed. Three groups of 10 mice treated with miloxacin (one group for each dose) were held in metabolism cages designed to ensure collections of urine free of feces. The glass collection vessels were shielded from light. The 24-h collection was promptly frozen and stored at -20°C. Studies on oxolinic acid were carried out in the same manner.
Studies in rats. A total of 114 male Sprague-Dawley rats weighing approximately 200 g were used. Fifteen groups of three rats each were dosed with miloxacin (five groups for each dose), and blood was collected from the abdominal aorta at the same intervals as with mice and treated in the same manner as described above. Three groups of three rats each were used for collection of urine (one group for each dose). (Table 1) . With all doses (20, 50, and 100 mg/kg), the serum concentrations ofmiloxacin were maximal at 0.5 h in mice and at 1 h in both rats and dogs. The peak concentrations in these species ranged from 15 to 27, from 37 to 59, and from 58 to 84 ,ug/ml at 20-, 50-, and 100-mg/kg doses, respectively. At the 20-mg/kg dose, the peak concentrations were highest in dogs and lowest in mice, whereas at the 50-and 100-mg/kg doses, they were highest in mice and lowest in rats. Miloxacin was rapidly removed from the circulating blood. Serum concentrations in all species fell below 6 ,ug/ml at 8 h, even at the highest dose, 100 mg/kg.
Oxolinic acid was more slowly absorbed than miloxacin. Peak serum concentrations of oxolinic acid occurred after 2 h at every dose in both rats and dogs, but in mice, they occurred after 0.5, 1, and 2 h at the doses of 20, 50 and 100 mg/kg, respectively. Furthermore, the peak concentrations of oxolinic acid were significantly lower than those of miloxacin. The bMean of six rats.
14C-labeled compound was administered orally at 50 mg/kg, have shown that this compound is absorbed and excreted rapidly and metabolized fairly extensively to biologically inactive metabolites (7, 8) . In the present studies, absorption and excretion of miloxacin in mice, rats, and beagle dogs were examined after single oral administration of three different doses (20, 50, and 100 mg/kg) and compared with those of oxolinic acid. Maximal serum levels of miloxacin occurred at 0.5 h in mice and 1 h in both rats and dogs after ingestion of 20-, 50-, and 100-mg/kg doses, whereas those of oxolinic acid appeared at 2 h except in mice, in whom they occurred 1 h after the 50-mg/kg dosage and 0.5 h after the 20-mg/ kg dosage. This indicates that miloxacin is absorbed somewhat more rapidly than oxolinic acid in these species. Peak concentrations of miloxacin were approximately two to four times higher than those of oxolinic acid. These findings suggest that miloxacin is more completely absorbed in the gastrointestinal tract in these species than oxolinic acid. Neither drug accumulated in the circulating blood, their serum levels decreasing rapidly to concentrations as low as 6 ,ug/ml at 8 h even at the highest doses.
As shown above, similar species differences in serum concentrations were observed with both miloxacin and oxolinic acid; these drugs were more rapidly absorbed to achieve higher concentrations in mice than in the other species. radioactivity within 24 h was higher in mice (60%) than in rats or dogs (each 30%). This species difference was reflected in the recoveries of intact miloxacin, namely, 7% in mice and 3 to 4% in the others (7, 8) . These results are almost identical to those obtained in the present studies and explain the higher recoveries of the antimicrobiological activity in mice than in the others. In rats with a 50-mg/kg dose, 4.6% of the miloxacin was excreted in bile within 20 h; the value was almost equal to that in urine of rats.
The studies with [14C]miloxacin (50 mg/kg) also
show that approximately an equal amount (5%) of intact miloxacin is recovered in bile within 20 h (35% recovery of 14C radioactivity) (7, 8) .
The preceding paper has shown that the antibacterial activity and spectrum of miloxacin are similar to those of oxolinic acid. The present studies have shown that the absorption and excretion of miloxacin are significantly better than those of oxolinic acid.
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